Ustekinumab for the treatment of psoriatic arthritis: an update.

Pharmacological treatment of psoriatic arthritis: a systematic literature review for the 2015 update of the EULAR recommendations for the management of psoriatic arthritis

Ramiro, S
Smolen, JS
Landewé, R
van der Heijde, D
Dougados, M
Emery, P
de Wit, M
Cutolo, M
Oliver, S
Gossec, L

March 2016

Objective: To update the evidence on the efficacy and safety of pharmacological agents in psoriatic ...

Drug survival and effectiveness of ustekinumab in patients with psoriatic arthritis. Real-life data from the biologic Apulian registry (BIOPURE)

Iannone, Florenzo
Santo, Leonardo
Bucci, Romano
Semeraro, Angelo
Carlino, Giorgio
Paoletti, Franco
Quarta, Laura
Leucci, Pierfrancesco
Zuccaro, Carmelo
Marsico, Antonio
Scioscia, Crescenzio
D’Onofrio, Francesca
Mazzotta, Daniela
Muratore, Maurizio
Cantatore, Francesco Paolo
Lapadula, Giovanni

January 2018

This study aims to evaluate the drug survival and effectiveness of ustekinumab in psoriatic arthriti...

The correlation of clinical efficacy, serum trough levels and antidrug antibodies in ustekinumab-treated patients with psoriasis in a clinical-practice setting

Menting, S. P.
van den Reek, J. M. P. A.
Baerveldt, E. M.
de Jong, E. M. G. J.
Prens, E. P.
Lecluse, L. L. A.
Wolbink, G. J.
van der Kleij, D.
Spuls, Ph I.
Rispens, T.

January 2015

Several therapeutic antibodies are available for the treatment of chronic plaque type psoriasis. Ust...

Ustekinumab for the treatment of psoriatic arthritis: an update

Davari, Parastoo
Leo, Michael S
Kamangar, Faranak
Fazel, Nasim

January 2014

Psoriatic arthritis occurs in 30% of psoriasis patients, and the treatment can be challenging in som...

Effectiveness and safety of ustekinumab in naïve or TNF-inhibitors failure psoriatic arthritis patients: a 24-month prospective multicentric study

Chimenti, Maria Sole
Ortolan, Augusta
Lorenzin, Mariagrazia
Triggianese, Paola
Talamonti, Marina
Costa, Luisa
Caso, Francesco
Favero, Marta
Teoli, Miriam
Galluzzo, Marco
Scarpa, Raffaele
Punzi, Leonardo
Perricone, Roberto
Ramonda, Roberta

January 2018

The current prospective observational study aimed to evaluate the long-term (24 months), real-life e...

Articles

Craig L Leonardi
Alexa B Kimball
Newman Yeilding
Cynthia Guzzo
Yuhua Wang
Shu Li
Lisa T Dooley
Kenneth B Gordon
For The
Phoenix Study Investigators

January 2008

Effi cacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with...

Efficacy and safety of ustekinumab in psoriatic arthritis patients with peripheral arthritis and physician-reported spondylitis: post-hoc analyses from two phase III, multicentre, double-blind, placebo-controlled studies (PSUMMIT-1/PSUMMIT-2)

Kavanaugh, Arthur
Puig, Lluis
Gottlieb, Alice B.
Ritchlin, Christopher
You, Yin
Li, Shu
Song, Michael
Randazzo, Bruce
Rahman, Proton
McInnes, Iain B.

November 2016

Objective: To evaluate ustekinumab efficacy and safety in psoriatic arthritis (PsA) patients with pe...

Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial

Ritchlin, C.
Rahman, P.
Kavanaugh, A.
McInnes, I.B.
Puig, L.
Li, S.
Wang, Y.
Shen, Y.-K.
Doyle, M. K.
Mendelsohn, A. M.
Gottlieb, A. B.
Perate, M.
Whitman, M.
Dooley, L. T.
Alten, R.
Birbara, C.
Boh, E.
Braun, J.
Budd, J.
Chattapadhyay, C.
Chudzik, D.
Claudepierre, P.
Cooper, R.
Drescher, E.
Dutz, J.
Edwards, C.
Elewski, B.
El-Kadi, H.
Erlacher, L.
Flipo, R.
Fretzin, S.
George, E.
Gladstein, G.
Griffin, R.
Grisanti, M.
Guenther, L.
Gulliver, W.
Hobbs, K.
Huang, E.
Ilivanova, E.
Jeka, S.
Khraishi, M.
Kokhan, M.
Korman, N.
Kunynetz, R.
Leonardi, C.
Lessard, C.
Lindquist, U.
Martin, A.
Matheson, R.
Murphy, F.
Nasonov, E.
Palmer, W.
Papp, K.
Rech, J.
Rell-Bakalarska, M.
Rich, P.
Rosen, C.
Rudin, A.
Ruppert-Roth, A.
Scheinecker, C.
Seigel, S.
Shaikh, S.
Sheeran, T.
Shergy, W.
Siegel, E.
Sierakowski, S.
Sofen, H.
Szanto, S.
Tahir, H.
Telegdy, E.
Toth, D.
Walker, D.
Wilson, A.
Witt, M.
Wollenhaupt, J.
Zoschke, D.
Zubrzycka, A.

January 2014

Objective: Assess ustekinumab efficacy (week 24/week 52) and safety (week 16/week 24/week 60) in pat...

New approved drugs for psoriatic arthritis

F.M. Perrotta
E. Lubrano

September 2016

Psoriatic arthritis (PsA) is a chronic inflammatory disease that possibly leads to structural damage...

Maintenance of clinical efficacy and radiographic benefit through two years of ustekinumab therapy in patients with active psoriatic arthritis : results from a randomized, placebo-controlled phase III trial

Kavanaugh, Arthur
Puig Sanz, Lluís
Gottlieb, Alice B.
Ritchlin, Christopher
Li, Shu
Wang, Yuhua
Mendelsohn, Alan M.
Song, Michael
Zhu, Yaowei
Rahman, Proton
McInnes, Iain B.
Universitat Autònoma de Barcelona

January 2015

To evaluate the efficacy and safety of ustekinumab through 2 years in adult patients with active pso...

Correspondence to

Immunology Rheumatology

January 2014

Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with acti...

Emerging drugs for psoriatic arthritis

Caso, Francesco
Del Puente, Antonio
Peluso, Rosario
Caso, Paolo
Girolimetto, Nicolò
Del Puente, Aurora
Scarpa, Raffaele
Costa, Luisa

January 2016

Introduction: The majority of Psoriatic Arthritis patients experience a good clinical response to an...

Ustekinumab Safety in Psoriasis, Psoriatic Arthritis, and Crohn's Disease: An Integrated Analysis of Phase II/III Clinical Development Programs.

Ghosh, Subrata
Gensler, Lianne S
Yang, Zijiang
Gasink, Chris
Chakravarty, Soumya D
Farahi, Kamyar
Ramachandran, Paraneedharan
Ott, Elyssa
Strober, Bruce E

June 2019

IntroductionTheoretical risks of biologic agents remain under study.ObjectiveThe aim of this study w...

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

Leonardi, Craig L
Kimball, Alexa B
Papp, Kim A
Yeilding, Newman
Guzzo, Cynthia
Wang, Yuhua
Li, Shu
Dooley, Lisa T
Gordon, Kenneth B
Ghislain, Pierre-Dominique

January 2008

Background: interleukins 12 and 23 have important roles in the pathophysiology of psoriasis. We asse...

Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo-controlled PSUMMIT-1 and PSUMMIT-2 trials

Kavanaugh, A.
Ritchlin, C.
Rahman, P.
Puig, L.
Gottlieb, A.B.
Li, S.
Wang, Y.
Noonan, L.
Brodmerkel, C.
Song, M.
Mendelsohn, A.M.
McInnes, I.B.

January 2014

Objective: Evaluate ustekinumab, an anti-interleukin (IL)-12 and IL-23 antibody, effects on radiogra...

Pharmacological treatment of psoriatic arthritis: a systematic literature review for the 2015 update of the EULAR recommendations for the management of psoriatic arthritis

Ramiro, S
Smolen, JS
Landewé, R
van der Heijde, D
Dougados, M
Emery, P
de Wit, M
Cutolo, M
Oliver, S
Gossec, L

March 2016

Objective: To update the evidence on the efficacy and safety of pharmacological agents in psoriatic ...

Drug survival and effectiveness of ustekinumab in patients with psoriatic arthritis. Real-life data from the biologic Apulian registry (BIOPURE)

Iannone, Florenzo
Santo, Leonardo
Bucci, Romano
Semeraro, Angelo
Carlino, Giorgio
Paoletti, Franco
Quarta, Laura
Leucci, Pierfrancesco
Zuccaro, Carmelo
Marsico, Antonio
Scioscia, Crescenzio
D’Onofrio, Francesca
Mazzotta, Daniela
Muratore, Maurizio
Cantatore, Francesco Paolo
Lapadula, Giovanni

January 2018

This study aims to evaluate the drug survival and effectiveness of ustekinumab in psoriatic arthriti...

The correlation of clinical efficacy, serum trough levels and antidrug antibodies in ustekinumab-treated patients with psoriasis in a clinical-practice setting

Menting, S. P.
van den Reek, J. M. P. A.
Baerveldt, E. M.
de Jong, E. M. G. J.
Prens, E. P.
Lecluse, L. L. A.
Wolbink, G. J.
van der Kleij, D.
Spuls, Ph I.
Rispens, T.

January 2015

Several therapeutic antibodies are available for the treatment of chronic plaque type psoriasis. Ust...

Ustekinumab for the treatment of psoriatic arthritis: an update

Davari, Parastoo
Leo, Michael S
Kamangar, Faranak
Fazel, Nasim

January 2014

Psoriatic arthritis occurs in 30% of psoriasis patients, and the treatment can be challenging in som...

Effectiveness and safety of ustekinumab in naïve or TNF-inhibitors failure psoriatic arthritis patients: a 24-month prospective multicentric study

Chimenti, Maria Sole
Ortolan, Augusta
Lorenzin, Mariagrazia
Triggianese, Paola
Talamonti, Marina
Costa, Luisa
Caso, Francesco
Favero, Marta
Teoli, Miriam
Galluzzo, Marco
Scarpa, Raffaele
Punzi, Leonardo
Perricone, Roberto
Ramonda, Roberta

January 2018

The current prospective observational study aimed to evaluate the long-term (24 months), real-life e...

Articles

Craig L Leonardi
Alexa B Kimball
Newman Yeilding
Cynthia Guzzo
Yuhua Wang
Shu Li
Lisa T Dooley
Kenneth B Gordon
For The
Phoenix Study Investigators

January 2008

Effi cacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with...

Efficacy and safety of ustekinumab in psoriatic arthritis patients with peripheral arthritis and physician-reported spondylitis: post-hoc analyses from two phase III, multicentre, double-blind, placebo-controlled studies (PSUMMIT-1/PSUMMIT-2)

Kavanaugh, Arthur
Puig, Lluis
Gottlieb, Alice B.
Ritchlin, Christopher
You, Yin
Li, Shu
Song, Michael
Randazzo, Bruce
Rahman, Proton
McInnes, Iain B.

November 2016

Objective: To evaluate ustekinumab efficacy and safety in psoriatic arthritis (PsA) patients with pe...

Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial

Ritchlin, C.
Rahman, P.
Kavanaugh, A.
McInnes, I.B.
Puig, L.
Li, S.
Wang, Y.
Shen, Y.-K.
Doyle, M. K.
Mendelsohn, A. M.
Gottlieb, A. B.
Perate, M.
Whitman, M.
Dooley, L. T.
Alten, R.
Birbara, C.
Boh, E.
Braun, J.
Budd, J.
Chattapadhyay, C.
Chudzik, D.
Claudepierre, P.
Cooper, R.
Drescher, E.
Dutz, J.
Edwards, C.
Elewski, B.
El-Kadi, H.
Erlacher, L.
Flipo, R.
Fretzin, S.
George, E.
Gladstein, G.
Griffin, R.
Grisanti, M.
Guenther, L.
Gulliver, W.
Hobbs, K.
Huang, E.
Ilivanova, E.
Jeka, S.
Khraishi, M.
Kokhan, M.
Korman, N.
Kunynetz, R.
Leonardi, C.
Lessard, C.
Lindquist, U.
Martin, A.
Matheson, R.
Murphy, F.
Nasonov, E.
Palmer, W.
Papp, K.
Rech, J.
Rell-Bakalarska, M.
Rich, P.
Rosen, C.
Rudin, A.
Ruppert-Roth, A.
Scheinecker, C.
Seigel, S.
Shaikh, S.
Sheeran, T.
Shergy, W.
Siegel, E.
Sierakowski, S.
Sofen, H.
Szanto, S.
Tahir, H.
Telegdy, E.
Toth, D.
Walker, D.
Wilson, A.
Witt, M.
Wollenhaupt, J.
Zoschke, D.
Zubrzycka, A.

January 2014

Objective: Assess ustekinumab efficacy (week 24/week 52) and safety (week 16/week 24/week 60) in pat...

New approved drugs for psoriatic arthritis

F.M. Perrotta
E. Lubrano

September 2016

Psoriatic arthritis (PsA) is a chronic inflammatory disease that possibly leads to structural damage...

Maintenance of clinical efficacy and radiographic benefit through two years of ustekinumab therapy in patients with active psoriatic arthritis : results from a randomized, placebo-controlled phase III trial

Kavanaugh, Arthur
Puig Sanz, Lluís
Gottlieb, Alice B.
Ritchlin, Christopher
Li, Shu
Wang, Yuhua
Mendelsohn, Alan M.
Song, Michael
Zhu, Yaowei
Rahman, Proton
McInnes, Iain B.
Universitat Autònoma de Barcelona

January 2015

To evaluate the efficacy and safety of ustekinumab through 2 years in adult patients with active pso...

Correspondence to

Immunology Rheumatology

January 2014

Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with acti...

Emerging drugs for psoriatic arthritis

Caso, Francesco
Del Puente, Antonio
Peluso, Rosario
Caso, Paolo
Girolimetto, Nicolò
Del Puente, Aurora
Scarpa, Raffaele
Costa, Luisa

January 2016

Introduction: The majority of Psoriatic Arthritis patients experience a good clinical response to an...

Ustekinumab Safety in Psoriasis, Psoriatic Arthritis, and Crohn's Disease: An Integrated Analysis of Phase II/III Clinical Development Programs.

Ghosh, Subrata
Gensler, Lianne S
Yang, Zijiang
Gasink, Chris
Chakravarty, Soumya D
Farahi, Kamyar
Ramachandran, Paraneedharan
Ott, Elyssa
Strober, Bruce E

June 2019

IntroductionTheoretical risks of biologic agents remain under study.ObjectiveThe aim of this study w...

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

Leonardi, Craig L
Kimball, Alexa B
Papp, Kim A
Yeilding, Newman
Guzzo, Cynthia
Wang, Yuhua
Li, Shu
Dooley, Lisa T
Gordon, Kenneth B
Ghislain, Pierre-Dominique

January 2008

Background: interleukins 12 and 23 have important roles in the pathophysiology of psoriasis. We asse...

Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo-controlled PSUMMIT-1 and PSUMMIT-2 trials

Kavanaugh, A.
Ritchlin, C.
Rahman, P.
Puig, L.
Gottlieb, A.B.
Li, S.
Wang, Y.
Noonan, L.
Brodmerkel, C.
Song, M.
Mendelsohn, A.M.
McInnes, I.B.

January 2014

Objective: Evaluate ustekinumab, an anti-interleukin (IL)-12 and IL-23 antibody, effects on radiogra...

Pharmacological treatment of psoriatic arthritis: a systematic literature review for the 2015 update of the EULAR recommendations for the management of psoriatic arthritis

Ramiro, S
Smolen, JS
Landewé, R
van der Heijde, D
Dougados, M
Emery, P
de Wit, M
Cutolo, M
Oliver, S
Gossec, L

March 2016

Objective: To update the evidence on the efficacy and safety of pharmacological agents in psoriatic ...

Drug survival and effectiveness of ustekinumab in patients with psoriatic arthritis. Real-life data from the biologic Apulian registry (BIOPURE)

Iannone, Florenzo
Santo, Leonardo
Bucci, Romano
Semeraro, Angelo
Carlino, Giorgio
Paoletti, Franco
Quarta, Laura
Leucci, Pierfrancesco
Zuccaro, Carmelo
Marsico, Antonio
Scioscia, Crescenzio
D’Onofrio, Francesca
Mazzotta, Daniela
Muratore, Maurizio
Cantatore, Francesco Paolo
Lapadula, Giovanni

January 2018

This study aims to evaluate the drug survival and effectiveness of ustekinumab in psoriatic arthriti...

The correlation of clinical efficacy, serum trough levels and antidrug antibodies in ustekinumab-treated patients with psoriasis in a clinical-practice setting

Menting, S. P.
van den Reek, J. M. P. A.
Baerveldt, E. M.
de Jong, E. M. G. J.
Prens, E. P.
Lecluse, L. L. A.
Wolbink, G. J.
van der Kleij, D.
Spuls, Ph I.
Rispens, T.

January 2015

Several therapeutic antibodies are available for the treatment of chronic plaque type psoriasis. Ust...

Ustekinumab for the treatment of psoriatic arthritis: an update.

Abstract

Extracted data

Ustekinumab for the treatment of psoriatic arthritis: an update.

Abstract

Extracted data

Related items

Related items